Our performance

Our performance

UCB continues its strategic growth path in a sustainable way. In 2019, we delivered a stronger than expected financial performance. We intensified our research and development investment as planned: in 2019, we started five Phase 3 programs with more than 4 000 patients enrolled. We made good progress on our long-term environmental goals. We also continued to adapt our ways of working to further embrace the opportunities and prepare for the launches in front of us. 

 

 

 

 

2018

2019

1

Environmental data is being compared to 2015, the year before we committed to our targets aimed at reducing UCB’s environmental footprint.

Continuous growth

Revenue (€ million)

4 632

4 913

rEBITDA/revenue ratio

30%

29%

R&D expense/revenue ratio

25%

26%

Innovating to create value for patients now and into the future

# Assets in pipeline

10

7

# First approvals

0

2

Respecting our communities and their environment1

Towards carbon neutrality

−30%

−35%

Reduced waste generation

−24%

−32%

Reduced water withdrawal

−1%

−27%

Helping our employees live a fulfilled life

Number of employees

7 500

7 606

% Female/male [whole company]

49%/51%

50%/50%

% Female/male [executive level]

29%/71%

33%/67%

% Female/male [board]

31%/69%

38%/62%

The financial data is reported for the period 1 January – 31 December. Financial data is reported semi-annually, and non-financial data is reported annually. The last integrated report was published on 28 February 2019.